2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors. 1991

W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486-004.

UI MeSH Term Description Entries
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
June 2009, Journal of medicinal chemistry,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
October 1992, Journal of medicinal chemistry,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
January 1996, Biochemistry,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
October 2001, Expert opinion on emerging drugs,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
February 1999, GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
January 1996, Methods in enzymology,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
November 2006, PLoS pathogens,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
November 1995, Journal of medicinal chemistry,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
October 1997, AIDS clinical care,
W S Saari, and J M Hoffman, and J S Wai, and T E Fisher, and C S Rooney, and A M Smith, and C M Thomas, and M E Goldman, and J A O'Brien, and J H Nunberg
April 2023, Communications chemistry,
Copied contents to your clipboard!